ES2195196T3 - Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion. - Google Patents
Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion.Info
- Publication number
- ES2195196T3 ES2195196T3 ES97953486T ES97953486T ES2195196T3 ES 2195196 T3 ES2195196 T3 ES 2195196T3 ES 97953486 T ES97953486 T ES 97953486T ES 97953486 T ES97953486 T ES 97953486T ES 2195196 T3 ES2195196 T3 ES 2195196T3
- Authority
- ES
- Spain
- Prior art keywords
- imprinting
- determination
- methods
- restoring
- normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan composiciones y procedimientos para el diagnóstico y el tratamiento de enfermedades que están asociadas con la impronta. Tales composiciones y procedimientos son útiles para restaurar un modelo normal de impronta. Las composiciones comprenden agentes farmacológicos que están implicados en la impronta y que se pueden usar en procedimientos preventivos y terapéuticos para restaurar un modelo normal de impronta. Tales agentes pueden restaurar un modelo normal de impronta en células. Otros procedimientos de la invención incluyen medios para identificar compuestos farmacológicos que ejercen su efecto restaurando la impronta normal en cromosomas y genes con impronta anómala. Además, la invención se podría usar también para identificar nuevos compuestos que ejercen su efecto restaurando la impronta normal en tejidos enfermos que presentan una impronta anómala subyacente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3409596P | 1996-12-30 | 1996-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2195196T3 true ES2195196T3 (es) | 2003-12-01 |
Family
ID=21874277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97953486T Expired - Lifetime ES2195196T3 (es) | 1996-12-30 | 1997-12-29 | Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0969822B1 (es) |
JP (2) | JP4913270B2 (es) |
AT (1) | ATE235190T1 (es) |
AU (1) | AU5722398A (es) |
CA (1) | CA2276306C (es) |
DE (1) | DE69720283T2 (es) |
DK (1) | DK0969822T3 (es) |
ES (1) | ES2195196T3 (es) |
WO (1) | WO1998029108A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6803195B1 (en) * | 1999-07-02 | 2004-10-12 | Ramot At Tel-Aviv University Ltd. | Facile detection of cancer and cancer risk based on level of coordination between alleles |
GB0107267D0 (en) * | 2001-03-23 | 2001-05-16 | Babraham Inst | Diagnostic method for determining the methylation state of cloned embryos |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
AU2002952944A0 (en) * | 2002-11-27 | 2002-12-12 | Human Genetic Signatures Pty Ltd | Restoration of methylation states in cells |
EP1641936B1 (en) | 2003-06-17 | 2010-08-04 | Human Genetic Signatures PTY Ltd. | Methods for genome amplification |
CA2537810C (en) | 2003-09-04 | 2012-12-18 | Human Genetic Signatures Pty Ltd | Nucleic acid detection assay |
US8168777B2 (en) | 2004-04-29 | 2012-05-01 | Human Genetic Signatures Pty. Ltd. | Bisulphite reagent treatment of nucleic acid |
JP4980219B2 (ja) | 2004-09-10 | 2012-07-18 | ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド | インターカレート型擬似ヌクレオチド(ipn)を含有するインターカレーティング核酸(ina)を含む増幅ブロッカー |
KR101293713B1 (ko) | 2004-12-03 | 2013-08-12 | 휴먼 제네틱 시그너처스 피티와이 엘티디 | 시토신의 화학적 변형에 의한 미생물 핵산의 단순화 방법 |
CN101203618B (zh) | 2005-05-26 | 2013-03-13 | 人类遗传标记控股有限公司 | 使用含有非常规碱基的引物的等温链置换扩增 |
CN101292046B (zh) | 2005-09-14 | 2013-03-13 | 人类遗传标记控股有限公司 | 健康状态的测定法 |
GB0607063D0 (en) | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
CN101918595A (zh) | 2007-11-27 | 2010-12-15 | 人类遗传标记控股有限公司 | 用于扩增和复制亚硫酸氢盐修饰的核酸的酶 |
US9732375B2 (en) | 2011-09-07 | 2017-08-15 | Human Genetic Signatures Pty. Ltd. | Molecular detection assay using direct treatment with a bisulphite reagent |
WO2018214249A1 (zh) * | 2017-05-22 | 2018-11-29 | 立森印迹诊断技术(无锡)有限公司 | 一种印记基因分级模型及其组成的系统和应用 |
CN112313345B (zh) * | 2018-05-18 | 2024-02-20 | 立森印迹诊断技术(无锡)有限公司 | 一种通过活检细胞样本诊断癌症的方法 |
CN110714075B (zh) * | 2018-07-13 | 2024-05-03 | 立森印迹诊断技术(无锡)有限公司 | 一种用于检测肺肿瘤良恶性程度的分级模型及其应用 |
CN110791563B (zh) * | 2018-08-01 | 2024-02-09 | 立森印迹诊断技术(无锡)有限公司 | 一种用于检测甲状腺肿瘤良恶性程度的分级模型及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
EP0631584A4 (en) * | 1991-02-28 | 1998-07-01 | Dana Farber Cancer Inst Inc | DIAGNOSIS AND THERAPY OF CANCER. |
EP0627436A1 (en) * | 1991-08-08 | 1994-12-07 | TSUMURA & CO. | Carcinostatic compound and production thereof |
US5356903A (en) * | 1993-04-22 | 1994-10-18 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolines |
-
1997
- 1997-12-29 JP JP53025498A patent/JP4913270B2/ja not_active Expired - Lifetime
- 1997-12-29 WO PCT/US1997/023991 patent/WO1998029108A2/en active IP Right Grant
- 1997-12-29 AU AU57223/98A patent/AU5722398A/en not_active Abandoned
- 1997-12-29 DE DE69720283T patent/DE69720283T2/de not_active Expired - Lifetime
- 1997-12-29 ES ES97953486T patent/ES2195196T3/es not_active Expired - Lifetime
- 1997-12-29 EP EP97953486A patent/EP0969822B1/en not_active Expired - Lifetime
- 1997-12-29 CA CA002276306A patent/CA2276306C/en not_active Expired - Lifetime
- 1997-12-29 DK DK97953486T patent/DK0969822T3/da active
- 1997-12-29 AT AT97953486T patent/ATE235190T1/de not_active IP Right Cessation
-
2008
- 2008-10-23 JP JP2008272942A patent/JP2009072197A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4913270B2 (ja) | 2012-04-11 |
CA2276306A1 (en) | 1998-07-09 |
DE69720283D1 (de) | 2003-04-30 |
WO1998029108A3 (en) | 1999-02-18 |
EP0969822A2 (en) | 2000-01-12 |
JP2001507703A (ja) | 2001-06-12 |
ATE235190T1 (de) | 2003-04-15 |
DK0969822T3 (da) | 2003-07-21 |
CA2276306C (en) | 2009-12-15 |
EP0969822B1 (en) | 2003-03-26 |
DE69720283T2 (de) | 2004-01-29 |
WO1998029108A2 (en) | 1998-07-09 |
JP2009072197A (ja) | 2009-04-09 |
AU5722398A (en) | 1998-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2195196T3 (es) | Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion. | |
DE69725293D1 (de) | N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität | |
DE69625518T2 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
NO20004803L (no) | Smilagening og anzurogenin for behandling av Alzheimers sykdom | |
DE69505962T2 (de) | Mittel zur künstlichen bräunung mit verbesserter stabilität | |
PL323490A1 (en) | Tetralinic compounds exibiting acitity against multgiple-drug refractoriness | |
BR9911040A (pt) | 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos | |
NO964486D0 (no) | Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering | |
ES2133329T3 (es) | Variantes de il-3 humana. | |
ATE237371T1 (de) | Blasenmukosa mit zellen für die rekonstruktion von geweben | |
DE69311896D1 (de) | Aminocyclohexylamide für antiarrhythmische und anästhetische verwendungen | |
TR200000455T2 (tr) | Alzheimer hastalığının tedavisinde fankinonun kullanılması. | |
PT841912E (pt) | 2-aminocarbonil-1,2-bis(metilsulfonil)-1-(substituido)-hidrazinas antitumor | |
DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
ES2156215T3 (es) | Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias. | |
MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
WO1999045103A3 (en) | Human spinal cord cell lines and methods of use therefor | |
EP1332756A3 (en) | Compositions and methods for restoring a normal pattern of imprinting to cells | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
BR9607178A (pt) | Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit | |
BR0113266A (pt) | Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla | |
Ramieri et al. | Growth‐associated protein‐43 immunoreactivity in human oral mucosa in dentate subjects, in edentulous patients and after implant‐anchored rehabilitation | |
AU7436098A (en) | Use of mizolastine for preparing a medicine for treating inflammation | |
Tsao et al. | Governance of Cutaneous Photocarcinogenesis by Chronic UVA-Exposed Dermal Fibroblasts |